McDermott Will & Emery advised GeNeuro on the deal. GeNeuro (Euronext Paris), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, announced its €7, 7...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here